VALIDUS PHARMS
SpecialtyVALIDUS PHARMS is a specialty pharmaceutical company focused on Cardiovascular, Gastroenterology, Neurology.
VALIDUS PHARMS's Key Drugs
VALIDUS PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
VALIDUS PHARMS's Recent FDA Approvals
VALIDUS PHARMS secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
VALIDUS PHARMS's Therapeutic Areas
VALIDUS PHARMS's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Gastroenterology, across 0 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
VALIDUS PHARMS's Top Competitors
VALIDUS PHARMS's closest competitors by therapeutic-area and drug-target overlap include WARNER CHILCOTT, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
VALIDUS PHARMS Pipeline Snapshot
Active clinical trials for VALIDUS PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1964-11-20
- Latest
- 2025-06-24
- Applications
- 12